Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry

Table 1

Baseline clinical data of the 1033 study patients.

HAQ (SD)		1.42±0.61
DAS28 (SD)		5.73±1.15
	High	773 (74.83%)
	Moderate	218 (21.1%)
	Low	15 (1.45%)
	Remission	15 (1.45%)
	Missing	12 (1.16%)
Steinbrocker functional class	I	37 (3.58%)
	II	706 (68.34%)
	III	247 (23.91%)
	IV	37 (3.58%)
	Missing	6 (0.58%)
Pain visual analogue scale (SD)		62.09±22.68
Global health assessment (SD)		59.81±22.47
Swollen joint count (SD)		9.73±5.54
Tender joint count (SD)		10.8±6.49
Anti-TNF drugs	Adalimumab	305 (29.53%)
	Etanercept	231 (22.36%)
	Infliximab	497 (48.11%)
Number of previous DMARDs	1	67 (6.49%)
	2	364 (35.24%)
	3	309 (29.91%)
	4	172 (16.65%)
	≥5	113 (10.94%)

HAQ: Health Assessment Questionnaire; DAS28: 28-joint disease activity score; TNF: tumour necrosis factor; DMARDS: disease modifying antirheumatic drugs; SD: standard deviation.